Principal Financial Group
RNAC icon

Principal Financial Group’s Cartesian Therapeutics RNAC Stock Holding History

Principal Financial Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-408
Closed -$7.96K – 2443
2024
Q1 		$7.96K Sell
408
-111
-21% -$2.35K ﹤0.01% 2421
2023
Q4 		$10.7K Hold
519
– – ﹤0.01% 2410
2023
Q3 		$16.5K Buy
519
+96
+23% +$3.21K ﹤0.01% 2424
2023
Q2 		$14.2K Buy
+423
New +$15.1K ﹤0.01% 2415
2022
Q4 		– Sell
-895
Closed -$44K – 2528
2022
Q3 		$44K Sell
895
-1,564
-64% -$85.9K ﹤0.01% 2415
2022
Q2 		$97K Buy
2,459
+762
+45% +$22.6K ﹤0.01% 2395
2022
Q1 		$63K Sell
1,697
-661
-28% -$41.3K ﹤0.01% 2475
2021
Q4 		$231K Sell
2,358
-2,921
-55% -$314K ﹤0.01% 2320
2021
Q3 		$659K Sell
5,279
-506
-9% -$61.1K ﹤0.01% 2099
2021
Q2 		$726K Buy
5,785
+2,601
+82% +$310K ﹤0.01% 2119
2021
Q1 		$432K Buy
3,184
+243
+8% +$30.2K ﹤0.01% 2194
2020
Q4 		$267K Buy
+2,941
New +$255K ﹤0.01% 2260

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Principal Financial Group's RNAC Position: Q2 2024 in Review

Principal Financial Group sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 408 shares — an estimated $7.96K sold.

Principal Financial Group first reported a position in RNAC in Q4 2020 and held it in 12 quarters. The position peaked at $726K in Q2 2021. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • Principal Financial Group reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 408 Cartesian Therapeutics shares in Q2 2024, an estimated $7.96K.
  • Principal Financial Group first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 12 quarters.
  • Principal Financial Group's Cartesian Therapeutics position peaked at $726K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.